Key takeaways
- NMN (nicotinamide mononucleotide) is a single nucleotide; NAD+ (nicotinamide adenine dinucleotide) is the coenzyme cells make from it. Neither contains amino acids, so neither is a peptide.
- A 2021 review states that “NAD+ is not cell permeable”, and says more studies are needed on how NMN enters cells.
- A meta-analysis of 12 NMN trials (513 people) found higher blood NAD levels, while most clinically relevant outcomes did not differ significantly from control.
- A 2026 analysis that pooled four trials of NAD+ and nicotinamide riboside found no significant difference from placebo in its main outcomes, and a rise in a kidney marker with NAD+.
- Drugs@FDA lists no approved product containing either. FDA puts NAD in Category 1 of its pharmacy-compounding list (updated 14 May 2026), and concluded on 29 September 2025 that NMN is not excluded from the definition of a dietary supplement.
01NAD+ vs NMN in one table
The same questions for both, dated 21 November 2026. Sources are at the end of the page.
| Question | NAD+ | NMN |
|---|---|---|
| What it is | A coenzyme: nicotinamide adenine dinucleotide. Its nonproprietary name is nadide | A single nucleotide: nicotinamide mononucleotide, a precursor that cells convert into NAD+ |
| Is it a peptide? | No. It contains no amino acids | No. It contains no amino acids |
| Formula and mass (PubChem) | C21H27N7O14P2, 663.4 g/mol | C11H15N2O8P, 334.22 g/mol |
| Place in the cell’s recycling route | The end product. Enzymes such as sirtuins, PARPs and CD38 use it up | One step before NAD+. Cells make it from nicotinamide or from nicotinamide riboside (NR) |
| Getting into cells (2021 review) | “NAD+ is not cell permeable” | A transporter has been reported in the small intestine; the review says further studies are needed |
| Human studies: what was measured | Its level in blood and urine, in a pilot study of 11 men (2019). Hospital admissions, deaths and heart measures, in a 2026 analysis that pooled four trials of NAD+ and NR | Blood NAD+ levels, in randomised trials of 30, 42 and 80 adults (2022 to 2023). Muscle insulin sensitivity in 25 women (2021). Walking, grip and gait tests in some trials |
| What pooled analyses found | No significant difference from placebo in the main outcomes, and a rise in a kidney marker with NAD+ (four trials of NAD+ and NR, 2026) | Higher blood NAD levels, while “most of the clinically relevant outcomes were not significantly different” from control (12 NMN trials, 513 people) |
| US status (21 Nov 2026) | Drugs@FDA lists no approved product. FDA’s 503A list puts NAD in Category 1, substances under evaluation, which is not an approval | Drugs@FDA lists no approved product. In a letter signed on 29 September 2025, FDA concluded that NMN “is not excluded from the definition of dietary supplement” |
| Sport (WADA) | Not named on the 2026 or 2027 List. The List’s classes include substances it does not name, so check with your anti-doping organisation | Not named on the 2026 or 2027 List. The List’s classes include substances it does not name, so check with your anti-doping organisation |
The trial counts in this table come from separate analyses, each with its own search and inclusion rules. They are not a like-for-like count of how much research each molecule has.
02Are NAD+ and NMN the same molecule?
NAD+ and NMN are different molecules, and neither is a peptide. A peptide is a chain of amino acids; these two are built from nucleotides. NMN, nicotinamide mononucleotide, is one nucleotide. NAD+, nicotinamide adenine dinucleotide, is the larger molecule that cells make from it. More on NAD+ itself: what NAD+ is, and why it is not a peptide. What counts as a peptide: what are peptides?
The recycling route in three steps, as a 2021 review in Nature Reviews Molecular Cell Biology describes it.
Nicotinamide or NR
Enzymes that use NAD+ release nicotinamide. The enzyme NAMPT converts nicotinamide into NMN, and two other enzymes convert nicotinamide riboside (NR) into NMN.
NMN
The middle of the route. Enzymes called NMNAT1, NMNAT2 and NMNAT3 convert NMN into NAD+.
NAD+
The product: a coenzyme for the redox reactions of energy metabolism. Sirtuins, PARPs and CD38 use it up, and the route starts again.
Getting into cells. The same review states that “NAD+ is not cell permeable”. For NMN it describes two routes: conversion to NR outside the cell before entry, and a transporter reported in the small intestine. It says further studies are needed to establish how NMN enters cells. The review’s authors declare competing interests, including research support from a company and, for one author, a patent on that transporter.
03What have human studies of NAD+ and NMN measured?
Two kinds of measure appear in these studies: levels in blood, and health measures such as walking tests or hospital admissions. A blood level is a lab value, not a health outcome.
NAD+ itself (T2; T1 for pooled small trials). A 2019 pilot study gave NAD+ to 8 healthy men aged 30 to 55 and saline to 3, and measured NAD+ and its breakdown products in their blood and urine. It was funded jointly by a company and a research institute; one author is a director of that company and medical director of the clinic where the study was run. A systematic review and meta-analysis published on 17 November 2026 pooled four randomised, placebo-controlled trials in 387 adults with symptomatic heart failure who were on standard treatment. The trials tested NAD+ or nicotinamide riboside (NR), not NMN. The primary outcomes were heart-failure hospital admissions, deaths from any cause and left ventricular ejection fraction, and none differed significantly from placebo. Nor did measures of heart size and strain, NT-proBNP (a blood marker of heart strain) or ALT (a liver marker). Serum creatinine, a kidney marker, rose with NAD+ (two trials, 209 people). The authors wrote that the treatments “appeared generally well tolerated in the short term”, but that the creatinine rise “warrants further evaluation”.
NMN (T1, small trials). Randomised, placebo-controlled trials have given NMN by mouth and measured NAD+ in blood: in 30 healthy adults over 12 weeks (2022), in 42 older men (2022) and in 80 healthy middle-aged adults over 60 days (2023). Each reported higher blood NAD+ in the NMN groups, and company employees are among the authors of all three. A 2021 trial in 25 postmenopausal women with prediabetes who were overweight or obese measured how muscle responds to insulin; its abstract reports no blood NAD+ result.
What pooled analyses of NMN found. A meta-analysis of 12 randomised trials with 513 participants found a significant rise in blood NAD levels with NMN, while “most of the clinically relevant outcomes were not significantly different” from control; it judged seven trials to raise some concerns about bias and five to be at high risk of it. Two 2025 meta-analyses disagree on walking speed. One, of nine trials with 412 middle-aged and older participants, reported a small gain in gait speed with NMN. The other, of NMN and NR in adults with a mean age over 60, found no significant effect of NMN on gait speed, grip strength or muscle mass, and concluded that current evidence “does not support” either for preserving muscle mass and function. A 2026 meta-analysis of 15 trials lasting 14 days to 24 weeks, 10 of them in its safety analysis, did not find more adverse events with NMN than without it, and found no significant change in body weight, fasting glucose or cholesterol measures, with a small fall in diastolic blood pressure. Its authors called for larger and longer trials to confirm efficacy and long-term safety.
Both together. A 2026 systematic review of human and rodent studies of NAD+ and its precursors, with 33 human studies of which 28 were randomised, found that NR and NMN by mouth changed NAD-related measures in blood, while effects on functional and other health-related outcomes were “heterogeneous and often null or endpoint-specific”. It classed a pilot study of NAD+ levels, which had no eligible clinical outcomes, as contextual evidence only. These analyses were not designed to compare NMN with NAD+, and the people in them differ. We found no published trial that compared NAD+ with NMN in people (PubMed, 21 November 2026). ClinicalTrials.gov lists one single-group study, planned for 20 patients, that gives both; it has no comparison group and has posted no results (NCT06776510).
04What is the US regulatory status of NAD+ and NMN?
NMN. FDA’s position has changed twice. In May 2022 it acknowledged a company’s new dietary ingredient notification for NMN. On 11 October 2022 it wrote to another company that NMN is excluded from the definition of a dietary supplement, because “NMN was not marketed as a dietary supplement, except unlawfully without an NDI notification, or as a food before FDA authorized it for investigation as a new drug.” Two organisations petitioned FDA to reverse that. In a letter signed on 29 September 2025, FDA granted the petition in part: “we now conclude that NMN is not excluded from the definition of dietary supplement”, because “NMN was marketed as a dietary supplement in the United States before such authorization”, by FDA’s account “as early as 2017”.
What the 2025 letter does not say. It does not say that NMN has been assessed as a medicine. Drugs@FDA lists no approved product containing it (21 November 2026), and FDA’s directory of supplement ingredients states that “FDA does not approve dietary supplements for safety and effectiveness”; that directory, current as of 1 May 2026, has no NMN entry. The letter also records that “NMN is an NDI”, a new dietary ingredient, and quotes FDA guidance that the agency’s acknowledgement of a notification “does not constitute an independent finding by FDA that the NDI and the dietary supplement that contains the NDI are safe”.
NAD+. Drugs@FDA lists no approved product containing NAD+ (searched as nadide and nicotinamide adenine dinucleotide, 21 November 2026). FDA’s list of bulk drug substances nominated for pharmacy compounding, updated 14 May 2026, places “Nicotinamide Adenine Dinucleotide (NAD)” in Category 1, “Bulk Drug Substances Under Evaluation”. A place on that list is not an approval. FDA’s 2025 letter concerns NMN: its only mention of NAD+ is as the molecule NMN is an intermediate for, and it takes no position on NAD+ as an ingredient. More: the NAD+ guide and FDA’s compounding categories.
- 16 May 2022FDA acknowledges an NMN notification
Its letter said acceptance for filing “is a procedural matter” and not a finding that the ingredient is safe.
- 11 Oct 2022FDA: NMN is excluded
FDA wrote to a company that NMN is excluded from the definition of a dietary supplement, and sent similar letters to every firm that had filed an NMN notification.
- 7 Mar 2023A petition asks FDA to reverse
Two organisations filed a citizen petition, amended on 24 December 2024.
- 29 Sep 2025FDA reverses its position
In its reply, FDA concluded that NMN “is not excluded from the definition of dietary supplement”.
- 14 May 2026NAD listed in Category 1
FDA’s list of substances nominated for pharmacy compounding, updated on this date, shows NAD in Category 1, under evaluation.
- 21 Nov 2026Neither is an approved medicine
Drugs@FDA lists no approved product containing NAD+ or NMN.
05Are NAD+ and NMN named on WADA’s Prohibited List?
Neither NAD+ nor NMN is named on WADA’s 2026 Prohibited List or on the 2027 List, in force from 1 January 2027 (both searched on 21 November 2026 for NAD, nadide, nicotinamide and NMN). Not being named does not settle it. The List’s classes include substances they do not name, with examples introduced by “including, but not limited to”, and anti-doping organisations decide how the List applies. Athletes should check with theirs. See peptides and anti-doping.
06What we don’t know about NAD+ and NMN
How the two compare in people
We found no published trial that compared NAD+ with NMN directly (PubMed, 21 Nov 2026). The studies above tested them separately, in different people, with different measures.
Whether a higher blood level changes health
The 2021 review lists as open questions whether restoring NAD+ levels in ageing humans “is safe” and whether it “will have beneficial effects”.
Long-term effects
The NMN trials pooled in 2026 lasted 14 days to 24 weeks. In the pooled trials of NAD+ and NR, a kidney marker rose with NAD+, and the authors said this “warrants further evaluation”.
What a given product contains
Only a lab report on that lot can show identity and purity: how to read a COA.
How we grade studies: evidence grades. Why we never state amounts: our policy.
This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.